Guerriero, Jennifer L. http://orcid.org/0000-0002-2104-5457
Lin, Jia-Ren
Pastorello, Ricardo G.
Du, Ziming http://orcid.org/0000-0003-2667-4989
Chen, Yu-An
Townsend, Madeline G.
Shimada, Kenichi
Hughes, Melissa E.
Ren, Siyang http://orcid.org/0000-0002-8516-6047
Tayob, Nabihah http://orcid.org/0000-0001-6088-167X
Zheng, Kelly
Mei, Shaolin http://orcid.org/0000-0002-2193-764X
Patterson, Alyssa
Taneja, Krishan L.
Metzger, Otto
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Lin, Nancy U.
Dillon, Deborah A.
Schnitt, Stuart J. http://orcid.org/0000-0002-3608-7828
Sorger, Peter K.
Mittendorf, Elizabeth A.
Santagata, Sandro http://orcid.org/0000-0002-7528-9668
Funding for this research was provided by:
Susan G. Komen (CCR18547597)
Terri Brodeur Breast Cancer Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA225088, P50CA168504, R37CA269499, U54-CA225088, U54-CA225088, U54-CA225088)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The Ludwig Center at Harvard Saverin Breast Cancer Research Fund at Dana-Farber Cancer Institute Stanley Riemer Family Fund at Dana-Farber Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The Ludwig Center at Harvard E.A.M. acknowledges the Rob and Karen Hale Distinguished Chair in Surgical Oncology for support
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 16 July 2022
Accepted: 2 December 2023
First Online: 2 January 2024
Competing interests
: D.A.D. consults for Novartis, receives funding from Canon, Inc., and is on the advisory board for Oncology Analytics, Inc. S.J.S. receives consulting fees from Venn Therapeutics. P.K.S. serves on the SAB or BOD of Glencoe Software, Applied Biomath, and RareCyte Inc. and has equity in these companies; he is a member of the NanoString SAB and is also co-founder of Glencoe Software, which contributes to and supports the open-source OME/OMERO image informatics software used in this paper. In the last five years, the Sorger lab has received research funding from Novartis and Merck. Sorger declares that none of these relationships are directly or indirectly related to the content of this manuscript. E.A.M. is on the SAB for AstraZeneca/Medimmune, Celgene, Genentech/Roche, Genomic Health (now Exact Sciences), Merck, Peregrine Pharmaceuticals, SELLAS Lifescience, and Tapimmune, is on steering committees for Bristol Myers Squibb and Roche/Genentech, has clinical trial support to her former institution (MD Anderson Cancer Center) from AstraZeneca/Medimmune, EMD-Serono, Galena Biopharma, and Genentech, has Genentech and Gilead support to a SU2C grant, and has sponsored Research Support to the laboratory from Glaxo-Smith Kline (GSK) and Eli Lilly. J.L.G. is a consultant for GSK, Codagenix, Duke Street Bio, and Array BioPharma/Pfizer and has received sponsored research support from GSK, Array BioPharma/Pfizer, Eli Lilly, and Merck. S.S. and K.S. report no relevant disclosures. S.M.T.: Consulting or Advisory Role: Novartis, Pfizer, Merck, Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Genentech/Roche, Eisai, Sanofi Genzyme, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, OncoPep, Kyowa Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Chugai Pharma, Ellipses Pharma, Infinity, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics; Institutional Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Odonate Therapeutics, Sanofi, Seattle Genetics.